BACKGROUND: The Fontan procedure is the final in a series of staged palliations for single-ventricle congenital heart disease, which encompasses rare and heterogeneous cardiac lesions. It represents an unusual and novel physiological state characterised by absence of a subpulmonary ventricle. AIMS: The population is growing steadily, prompting creation of this registry to study their epidemiology, demographic trends, treatment and outcomes. METHODS: This multicentre, binational, prospective and retrospective, web-based registry involving all congenital cardiac centres in the region has identified nearly all Fontan patients in Australia and New Zealand. Patients identified retrospectively were approached for recruitment. New recipients are automatically enrolled prospectively unless they choose to opt-out. Follow-up data are collected yearly. RESULTS: Baseline data were obtained in 1072 patients as at 1 January 2011. Ninety-nine patients died; 64 were lost to follow up. Forty-four per cent of patients lost were between 20 and 30 years of age. The size of the Fontan population is increasing steadily. Among 973 living patients, 541 (56%) gave consent for prospective collection of follow up. Between 1 January 2011 and 1 January 2013, an additional 47 subjects were enrolled prospectively. The current proportion of patients operated with hypoplastic left heart syndrome is currently 29% and is growing rapidly. CONCLUSION: The population surviving after the Fontan procedure has been growing in recent decades, especially since survival with hypoplastic left heart syndrome has improved. The Australia and New Zealand Fontan Registry provides population-based data, and only large databases like this will give opportunities for understanding the population and performing prospective trials.
BACKGROUND: The Fontan procedure is the final in a series of staged palliations for single-ventricle congenital heart disease, which encompasses rare and heterogeneous cardiac lesions. It represents an unusual and novel physiological state characterised by absence of a subpulmonary ventricle. AIMS: The population is growing steadily, prompting creation of this registry to study their epidemiology, demographic trends, treatment and outcomes. METHODS: This multicentre, binational, prospective and retrospective, web-based registry involving all congenital cardiac centres in the region has identified nearly all Fontan patients in Australia and New Zealand. Patients identified retrospectively were approached for recruitment. New recipients are automatically enrolled prospectively unless they choose to opt-out. Follow-up data are collected yearly. RESULTS: Baseline data were obtained in 1072 patients as at 1 January 2011. Ninety-nine patients died; 64 were lost to follow up. Forty-four per cent of patients lost were between 20 and 30 years of age. The size of the Fontan population is increasing steadily. Among 973 living patients, 541 (56%) gave consent for prospective collection of follow up. Between 1 January 2011 and 1 January 2013, an additional 47 subjects were enrolled prospectively. The current proportion of patients operated with hypoplastic left heart syndrome is currently 29% and is growing rapidly. CONCLUSION: The population surviving after the Fontan procedure has been growing in recent decades, especially since survival with hypoplastic left heart syndrome has improved. The Australia and New Zealand Fontan Registry provides population-based data, and only large databases like this will give opportunities for understanding the population and performing prospective trials.
Authors: Kathleen Gilbert; Nickolas Forsch; Sanjeet Hegde; Charlene Mauger; Jeffrey H Omens; James C Perry; Beau Pontré; Avan Suinesiaputra; Alistair A Young; Andrew D McCulloch Journal: J Cardiovasc Transl Res Date: 2018-01-02 Impact factor: 4.132
Authors: Ganesh K Gnanappa; David S Celermajer; Gary F Sholler; Tom Gentles; David Winlaw; Yves d'Udekem; Julian Ayer Journal: Pediatr Cardiol Date: 2016-10-27 Impact factor: 1.655
Authors: Derek L Tran; Hannah Gibson; Andrew J Maiorana; Charlotte E Verrall; David W Baker; Melanie Clode; David R Lubans; Diana Zannino; Andrew Bullock; Suzie Ferrie; Julie Briody; Peter Simm; Vishva Wijesekera; Michelle D'Almeida; Sally E Gosbell; Glen M Davis; Robert Weintraub; Anthony C Keech; Rajesh Puranik; Martin Ugander; Robert Justo; Dominica Zentner; Avik Majumdar; Leeanne Grigg; Jeff S Coombes; Yves d'Udekem; Norman R Morris; Julian Ayer; David S Celermajer; Rachael Cordina Journal: Front Pediatr Date: 2022-01-06 Impact factor: 3.418
Authors: Michael Daley; Edward Buratto; Gregory King; Leeanne Grigg; Ajay Iyengar; Nelson Alphonso; Andrew Bullock; David S Celermajer; Julian Ayer; Terry Robertson; Yves d'Udekem; Igor E Konstantinov Journal: J Am Heart Assoc Date: 2022-05-27 Impact factor: 6.106
Authors: Elena Hadjicosta; Rodney Franklin; Anna Seale; Oliver Stumper; Victor Tsang; David R Anderson; Christina Pagel; Sonya Crowe; Ferran Espuny Pujol; Deborah Ridout; Kate L Brown Journal: Heart Date: 2022-06-10 Impact factor: 7.365
Authors: Karin du Plessis; Rebecca Peters; Ingrid King; Kirsty Robertson; Jonathan Mackley; Rachel Maree; Tracy Stanley; Louise Pickford; Brian Rose; Matthew Orchard; Helen Stewart; Yves d'Udekem Journal: Int J Cardiol Heart Vasc Date: 2018-03-09
Authors: Kate H Marshall; Yves D'Udekem; Gary F Sholler; Alexander R Opotowsky; Daniel S J Costa; Louise Sharpe; David S Celermajer; David S Winlaw; Jane W Newburger; Nadine A Kasparian Journal: J Am Heart Assoc Date: 2020-03-16 Impact factor: 5.501
Authors: Chin L Poh; Rachael L Cordina; Ajay J Iyengar; Diana Zannino; Leeanne E Grigg; Gavin R Wheaton; Andrew Bullock; Julian Ayer; Nelson Alphonso; Thomas L Gentles; David S Celermajer; Yves d'Udekem Journal: Int J Cardiol Heart Vasc Date: 2021-07-07